Circulating Th2 cell reduction and Th1/Th2 imbalance are correlated with primary Sjogren’s syndrome-associated interstitial lung disease

Objective Primary Sjogren’s syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and the involvement and dysfunction of multiple organs and tissues. Interstitial lung disease (ILD) is the most common type of respiratory system...

Full description

Saved in:
Bibliographic Details
Published inArthritis research & therapy Vol. 24; no. 1; pp. 121 - 9
Main Authors Shi, Lei, Wang, Jia, Guo, Hong-Xia, Han, Xiao-Lei, Tang, Yu-Ping, Liu, Guang-Ying
Format Journal Article
LanguageEnglish
Published London BioMed Central 23.05.2022
BioMed Central Ltd
BMC
Subjects
Online AccessGet full text
ISSN1478-6362
1478-6354
1478-6362
DOI10.1186/s13075-022-02811-z

Cover

Loading…
Abstract Objective Primary Sjogren’s syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and the involvement and dysfunction of multiple organs and tissues. Interstitial lung disease (ILD) is the most common type of respiratory system damage. This study ascertained the factors related to ILD in patients with pSS (pSS-ILD), such as altered levels of circulating lymphocyte subtypes. Methods Eighty healthy controls and 142 patients diagnosed with pSS were included. The pSS patients were classified into groups with pSS-ILD or pSS without ILD (pSS-non-ILD). Baseline clinical and laboratory data were collected for all subjects, including the levels of lymphocytes measured by modified flow cytometry. Results The pSS-ILD patients were older, had higher ESSDAI scores, had higher positivity rates for anti-SSB and anti-Ro52 antibodies, and had more frequent symptoms of respiratory system involvement than pSS-non-ILD patients. pSS-ILD patients had the lowest Th2 cell counts among the three groups. Although the absolute numbers of Treg and NK cells were lower in pSS patients with and without ILD than in the healthy controls, there was no significant difference between the two pSS groups. The Th1/Th2 ratio was significantly higher in patients with ILD than in patients without ILD. Further analysis showed that older age (OR=1.084), lower Th2 count (OR=0.947), higher Th1/Th2 ratio (OR=1.021), and positivity for anti-SSB (OR=3.620) and anti-Ro52 (OR=5.184) antibodies were associated with the occurrence of ILD in patients with pSS. Conclusion Decreased circulating Th2 cells and an elevated Th1/Th2 ratio may be the immunological mechanism underlying the development of ILD in pSS patients.
AbstractList Objective Primary Sjogren’s syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and the involvement and dysfunction of multiple organs and tissues. Interstitial lung disease (ILD) is the most common type of respiratory system damage. This study ascertained the factors related to ILD in patients with pSS (pSS-ILD), such as altered levels of circulating lymphocyte subtypes. Methods Eighty healthy controls and 142 patients diagnosed with pSS were included. The pSS patients were classified into groups with pSS-ILD or pSS without ILD (pSS-non-ILD). Baseline clinical and laboratory data were collected for all subjects, including the levels of lymphocytes measured by modified flow cytometry. Results The pSS-ILD patients were older, had higher ESSDAI scores, had higher positivity rates for anti-SSB and anti-Ro52 antibodies, and had more frequent symptoms of respiratory system involvement than pSS-non-ILD patients. pSS-ILD patients had the lowest Th2 cell counts among the three groups. Although the absolute numbers of Treg and NK cells were lower in pSS patients with and without ILD than in the healthy controls, there was no significant difference between the two pSS groups. The Th1/Th2 ratio was significantly higher in patients with ILD than in patients without ILD. Further analysis showed that older age (OR=1.084), lower Th2 count (OR=0.947), higher Th1/Th2 ratio (OR=1.021), and positivity for anti-SSB (OR=3.620) and anti-Ro52 (OR=5.184) antibodies were associated with the occurrence of ILD in patients with pSS. Conclusion Decreased circulating Th2 cells and an elevated Th1/Th2 ratio may be the immunological mechanism underlying the development of ILD in pSS patients.
Objective Primary Sjogren’s syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and the involvement and dysfunction of multiple organs and tissues. Interstitial lung disease (ILD) is the most common type of respiratory system damage. This study ascertained the factors related to ILD in patients with pSS (pSS-ILD), such as altered levels of circulating lymphocyte subtypes. Methods Eighty healthy controls and 142 patients diagnosed with pSS were included. The pSS patients were classified into groups with pSS-ILD or pSS without ILD (pSS-non-ILD). Baseline clinical and laboratory data were collected for all subjects, including the levels of lymphocytes measured by modified flow cytometry. Results The pSS-ILD patients were older, had higher ESSDAI scores, had higher positivity rates for anti-SSB and anti-Ro52 antibodies, and had more frequent symptoms of respiratory system involvement than pSS-non-ILD patients. pSS-ILD patients had the lowest Th2 cell counts among the three groups. Although the absolute numbers of Treg and NK cells were lower in pSS patients with and without ILD than in the healthy controls, there was no significant difference between the two pSS groups. The Th1/Th2 ratio was significantly higher in patients with ILD than in patients without ILD. Further analysis showed that older age (OR=1.084), lower Th2 count (OR=0.947), higher Th1/Th2 ratio (OR=1.021), and positivity for anti-SSB (OR=3.620) and anti-Ro52 (OR=5.184) antibodies were associated with the occurrence of ILD in patients with pSS. Conclusion Decreased circulating Th2 cells and an elevated Th1/Th2 ratio may be the immunological mechanism underlying the development of ILD in pSS patients.
Primary Sjogren's syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and the involvement and dysfunction of multiple organs and tissues. Interstitial lung disease (ILD) is the most common type of respiratory system damage. This study ascertained the factors related to ILD in patients with pSS (pSS-ILD), such as altered levels of circulating lymphocyte subtypes. Eighty healthy controls and 142 patients diagnosed with pSS were included. The pSS patients were classified into groups with pSS-ILD or pSS without ILD (pSS-non-ILD). Baseline clinical and laboratory data were collected for all subjects, including the levels of lymphocytes measured by modified flow cytometry. The pSS-ILD patients were older, had higher ESSDAI scores, had higher positivity rates for anti-SSB and anti-Ro52 antibodies, and had more frequent symptoms of respiratory system involvement than pSS-non-ILD patients. pSS-ILD patients had the lowest Th2 cell counts among the three groups. Although the absolute numbers of Treg and NK cells were lower in pSS patients with and without ILD than in the healthy controls, there was no significant difference between the two pSS groups. The Th1/Th2 ratio was significantly higher in patients with ILD than in patients without ILD. Further analysis showed that older age (OR=1.084), lower Th2 count (OR=0.947), higher Th1/Th2 ratio (OR=1.021), and positivity for anti-SSB (OR=3.620) and anti-Ro52 (OR=5.184) antibodies were associated with the occurrence of ILD in patients with pSS. Decreased circulating Th2 cells and an elevated Th1/Th2 ratio may be the immunological mechanism underlying the development of ILD in pSS patients.
Primary Sjogren's syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and the involvement and dysfunction of multiple organs and tissues. Interstitial lung disease (ILD) is the most common type of respiratory system damage. This study ascertained the factors related to ILD in patients with pSS (pSS-ILD), such as altered levels of circulating lymphocyte subtypes. Eighty healthy controls and 142 patients diagnosed with pSS were included. The pSS patients were classified into groups with pSS-ILD or pSS without ILD (pSS-non-ILD). Baseline clinical and laboratory data were collected for all subjects, including the levels of lymphocytes measured by modified flow cytometry. The pSS-ILD patients were older, had higher ESSDAI scores, had higher positivity rates for anti-SSB and anti-Ro52 antibodies, and had more frequent symptoms of respiratory system involvement than pSS-non-ILD patients. pSS-ILD patients had the lowest Th2 cell counts among the three groups. Although the absolute numbers of Treg and NK cells were lower in pSS patients with and without ILD than in the healthy controls, there was no significant difference between the two pSS groups. The Th1/Th2 ratio was significantly higher in patients with ILD than in patients without ILD. Further analysis showed that older age (OR=1.084), lower Th2 count (OR=0.947), higher Th1/Th2 ratio (OR=1.021), and positivity for anti-SSB (OR=3.620) and anti-Ro52 (OR=5.184) antibodies were associated with the occurrence of ILD in patients with pSS. Decreased circulating Th2 cells and an elevated Th1/Th2 ratio may be the immunological mechanism underlying the development of ILD in pSS patients.
Abstract Objective Primary Sjogren’s syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and the involvement and dysfunction of multiple organs and tissues. Interstitial lung disease (ILD) is the most common type of respiratory system damage. This study ascertained the factors related to ILD in patients with pSS (pSS-ILD), such as altered levels of circulating lymphocyte subtypes. Methods Eighty healthy controls and 142 patients diagnosed with pSS were included. The pSS patients were classified into groups with pSS-ILD or pSS without ILD (pSS-non-ILD). Baseline clinical and laboratory data were collected for all subjects, including the levels of lymphocytes measured by modified flow cytometry. Results The pSS-ILD patients were older, had higher ESSDAI scores, had higher positivity rates for anti-SSB and anti-Ro52 antibodies, and had more frequent symptoms of respiratory system involvement than pSS-non-ILD patients. pSS-ILD patients had the lowest Th2 cell counts among the three groups. Although the absolute numbers of Treg and NK cells were lower in pSS patients with and without ILD than in the healthy controls, there was no significant difference between the two pSS groups. The Th1/Th2 ratio was significantly higher in patients with ILD than in patients without ILD. Further analysis showed that older age (OR=1.084), lower Th2 count (OR=0.947), higher Th1/Th2 ratio (OR=1.021), and positivity for anti-SSB (OR=3.620) and anti-Ro52 (OR=5.184) antibodies were associated with the occurrence of ILD in patients with pSS. Conclusion Decreased circulating Th2 cells and an elevated Th1/Th2 ratio may be the immunological mechanism underlying the development of ILD in pSS patients.
Objective Primary Sjogren's syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and the involvement and dysfunction of multiple organs and tissues. Interstitial lung disease (ILD) is the most common type of respiratory system damage. This study ascertained the factors related to ILD in patients with pSS (pSS-ILD), such as altered levels of circulating lymphocyte subtypes. Methods Eighty healthy controls and 142 patients diagnosed with pSS were included. The pSS patients were classified into groups with pSS-ILD or pSS without ILD (pSS-non-ILD). Baseline clinical and laboratory data were collected for all subjects, including the levels of lymphocytes measured by modified flow cytometry. Results The pSS-ILD patients were older, had higher ESSDAI scores, had higher positivity rates for anti-SSB and anti-Ro52 antibodies, and had more frequent symptoms of respiratory system involvement than pSS-non-ILD patients. pSS-ILD patients had the lowest Th2 cell counts among the three groups. Although the absolute numbers of Treg and NK cells were lower in pSS patients with and without ILD than in the healthy controls, there was no significant difference between the two pSS groups. The Th1/Th2 ratio was significantly higher in patients with ILD than in patients without ILD. Further analysis showed that older age (OR=1.084), lower Th2 count (OR=0.947), higher Th1/Th2 ratio (OR=1.021), and positivity for anti-SSB (OR=3.620) and anti-Ro52 (OR=5.184) antibodies were associated with the occurrence of ILD in patients with pSS. Conclusion Decreased circulating Th2 cells and an elevated Th1/Th2 ratio may be the immunological mechanism underlying the development of ILD in pSS patients. Keywords: Primary Sjogren syndrome (pSS), Interstitial lung disease (ILD), Th2 cells, Th1/Th2 ratio
Primary Sjogren's syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and the involvement and dysfunction of multiple organs and tissues. Interstitial lung disease (ILD) is the most common type of respiratory system damage. This study ascertained the factors related to ILD in patients with pSS (pSS-ILD), such as altered levels of circulating lymphocyte subtypes.OBJECTIVEPrimary Sjogren's syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and the involvement and dysfunction of multiple organs and tissues. Interstitial lung disease (ILD) is the most common type of respiratory system damage. This study ascertained the factors related to ILD in patients with pSS (pSS-ILD), such as altered levels of circulating lymphocyte subtypes.Eighty healthy controls and 142 patients diagnosed with pSS were included. The pSS patients were classified into groups with pSS-ILD or pSS without ILD (pSS-non-ILD). Baseline clinical and laboratory data were collected for all subjects, including the levels of lymphocytes measured by modified flow cytometry.METHODSEighty healthy controls and 142 patients diagnosed with pSS were included. The pSS patients were classified into groups with pSS-ILD or pSS without ILD (pSS-non-ILD). Baseline clinical and laboratory data were collected for all subjects, including the levels of lymphocytes measured by modified flow cytometry.The pSS-ILD patients were older, had higher ESSDAI scores, had higher positivity rates for anti-SSB and anti-Ro52 antibodies, and had more frequent symptoms of respiratory system involvement than pSS-non-ILD patients. pSS-ILD patients had the lowest Th2 cell counts among the three groups. Although the absolute numbers of Treg and NK cells were lower in pSS patients with and without ILD than in the healthy controls, there was no significant difference between the two pSS groups. The Th1/Th2 ratio was significantly higher in patients with ILD than in patients without ILD. Further analysis showed that older age (OR=1.084), lower Th2 count (OR=0.947), higher Th1/Th2 ratio (OR=1.021), and positivity for anti-SSB (OR=3.620) and anti-Ro52 (OR=5.184) antibodies were associated with the occurrence of ILD in patients with pSS.RESULTSThe pSS-ILD patients were older, had higher ESSDAI scores, had higher positivity rates for anti-SSB and anti-Ro52 antibodies, and had more frequent symptoms of respiratory system involvement than pSS-non-ILD patients. pSS-ILD patients had the lowest Th2 cell counts among the three groups. Although the absolute numbers of Treg and NK cells were lower in pSS patients with and without ILD than in the healthy controls, there was no significant difference between the two pSS groups. The Th1/Th2 ratio was significantly higher in patients with ILD than in patients without ILD. Further analysis showed that older age (OR=1.084), lower Th2 count (OR=0.947), higher Th1/Th2 ratio (OR=1.021), and positivity for anti-SSB (OR=3.620) and anti-Ro52 (OR=5.184) antibodies were associated with the occurrence of ILD in patients with pSS.Decreased circulating Th2 cells and an elevated Th1/Th2 ratio may be the immunological mechanism underlying the development of ILD in pSS patients.CONCLUSIONDecreased circulating Th2 cells and an elevated Th1/Th2 ratio may be the immunological mechanism underlying the development of ILD in pSS patients.
ArticleNumber 121
Audience Academic
Author Tang, Yu-Ping
Liu, Guang-Ying
Han, Xiao-Lei
Shi, Lei
Wang, Jia
Guo, Hong-Xia
Author_xml – sequence: 1
  givenname: Lei
  surname: Shi
  fullname: Shi, Lei
  email: 56443961@qq.com
  organization: Department of Rheumatology, The Second Hospital of Shanxi Medical University
– sequence: 2
  givenname: Jia
  surname: Wang
  fullname: Wang, Jia
  organization: Department of Rheumatology, The Second Hospital of Shanxi Medical University
– sequence: 3
  givenname: Hong-Xia
  surname: Guo
  fullname: Guo, Hong-Xia
  organization: Department of Cardiology, The Second Hospital of Shanxi Medical University
– sequence: 4
  givenname: Xiao-Lei
  surname: Han
  fullname: Han, Xiao-Lei
  email: sydey_hxl@sina.com
  organization: Department of Mental Health, The Second Hospital of Shanxi Medical University
– sequence: 5
  givenname: Yu-Ping
  surname: Tang
  fullname: Tang, Yu-Ping
  organization: Department of Rheumatology, The Second Hospital of Shanxi Medical University
– sequence: 6
  givenname: Guang-Ying
  surname: Liu
  fullname: Liu, Guang-Ying
  organization: Department of Rheumatology, The Second Hospital of Shanxi Medical University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35606782$$D View this record in MEDLINE/PubMed
BookMark eNp9kstu1TAURSNURB_wAwxQJCZM0voRJ84EqbriUakSA8rYcuyT1FeJXeykqB0x5g_4Pb6Ecx-lvRWqoijO8drbPvY-zPZ88JBlryk5plRWJ4lyUouCMIavpLS4fZYd0LKWRcUrtvdgvJ8dprQkSDasfJHtc1GRqpbsIPu1cNHMg56c7_OLS5YbGIY8gp3N5ILPtbdYpierKTe2etDeQK4j5CbECCgEm_9w02V-Fd2o403-dRn6CP7Pz98pTzfexjBCoVMKxq1h5yeIaXKT00M-zLisdQl0gpfZ804PCV5tv0fZt48fLhafi_Mvn84Wp-eFEbyeCitIadvSdFRie5WoOjBat3WH_Qgt6k40mrcN_gsuRck4Y52Vhlai5aCp5EfZ2cbXBr1U222roJ1aF0LslY6TMwMo0lIQhFpBO1M2gjam5K2wpRCMt7Um6PV-43U1tyNYA36Ketgx3Z3x7lL14Vo1lAkpGjR4tzWI4fsMaVKjS6s70B7CnBSrKtmQWpIS0beP0GWYo8ejQqqWtJSS8Huq19iA813Adc3KVJ3WpCo5YjVSx_-h8LEwOoMx6xzWdwRvHjb6r8O7JCEgN4CJIaUInTJu0qsMobMbFCVqFVq1Ca3CKKp1aNUtStkj6Z37kyK-ESWEfQ_x_jSeUP0FJsgAiA
CitedBy_id crossref_primary_10_1016_j_autrev_2024_103600
crossref_primary_10_1136_bmjresp_2023_002076
crossref_primary_10_3389_fimmu_2024_1345381
crossref_primary_10_1080_03007995_2023_2281501
crossref_primary_10_1186_s12865_023_00550_7
crossref_primary_10_12968_hmed_2024_0572
crossref_primary_10_1093_rheumatology_kead070
crossref_primary_10_2147_JAA_S383128
crossref_primary_10_1167_iovs_64_12_7
crossref_primary_10_1016_j_heliyon_2024_e31751
crossref_primary_10_1097_HC9_0000000000000269
crossref_primary_10_3389_fmolb_2024_1448946
crossref_primary_10_3389_fimmu_2024_1435525
crossref_primary_10_1007_s10753_022_01747_5
Cites_doi 10.1111/j.1748-5827.2011.01024.x
10.3389/fimmu.2019.01327
10.1136/annrheumdis-2016-210571
10.1371/journal.pone.0073774
10.1164/rccm.2009-040GL
10.2353/ajpath.2006.051160
10.1007/s00296-012-2561-7
10.1136/ard.61.6.554
10.1136/annrheumdis-2018-213036
10.1016/j.reuma.2015.10.010
10.1186/s12952-017-0069-0
10.1136/ard.2009.114264
10.1007/s10067-018-4289-6
10.1177/2040622320916014
10.1007/s00296-009-1152-8
10.1038/nri911
10.1093/rheumatology/kes311
10.1042/BST0350661
10.1177/2040622320944802
10.1136/ard.59.9.709
10.3760/cma.j.issn.0578-1426.2018.08.005
10.1186/ar3097
10.1136/ard.2005.049924
10.1002/art.24435
10.1016/j.cyto.2014.06.008
10.1158/1055-9965.EPI-04-0624
10.1111/1756-185X.13334
10.1016/j.jaut.2009.10.004
10.21037/jtd.2018.03.120
10.1016/j.lab.2006.01.001
10.1007/s10238-020-00623-6
10.1046/j.1365-2249.1998.00705.x
10.1378/chest.128.4.2971
10.1136/jcp.2003.015495
10.1136/bmj.h6819
10.1164/rccm.200502-244OC
10.1111/cei.12341
ContentType Journal Article
Copyright The Author(s) 2022
2022. The Author(s).
COPYRIGHT 2022 BioMed Central Ltd.
2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2022
– notice: 2022. The Author(s).
– notice: COPYRIGHT 2022 BioMed Central Ltd.
– notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13075-022-02811-z
DatabaseName Springer Nature OA Free Journals
CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Proquest Medical Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database

PubMed



MEDLINE - Academic
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1478-6362
EndPage 9
ExternalDocumentID oai_doaj_org_article_0b1e501d51fc49519c43b5d45523b7a0
PMC9125859
A706434887
35606782
10_1186_s13075_022_02811_z
Genre Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: Doctoral Fund of the Second Hospital of Shanxi Medical University
  grantid: No.202001-4
– fundername: Natural Science Research Project of Shanxi Province
  grantid: No. 20210302123281
– fundername: ;
  grantid: No. 20210302123281
– fundername: ;
  grantid: No.202001-4
GroupedDBID ---
.GJ
0R~
23N
2WC
4.4
5GY
5VS
6J9
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
ABUWG
ACGFS
ACJQM
ADBBV
ADUKV
AEGXH
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIAM
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
E3Z
EBD
EBLON
EMOBN
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
HZ~
INH
INR
ITC
KQ8
M1P
O5R
O5S
O9-
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
RBZ
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
U2A
UKHRP
WOQ
AAYXX
ALIPV
CITATION
-5E
-5G
-A0
-BR
3V.
ACRMQ
ADINQ
C24
IAO
IHR
NPM
Z7U
PMFND
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c537t-d504db4cf18478656fecaab7f7825a57f59a3b97f7538542322fd8c165b3ea183
IEDL.DBID C6C
ISSN 1478-6362
1478-6354
IngestDate Wed Aug 27 01:32:23 EDT 2025
Thu Aug 21 18:25:50 EDT 2025
Fri Sep 05 03:26:07 EDT 2025
Fri Jul 25 04:16:30 EDT 2025
Tue Jun 17 21:43:41 EDT 2025
Tue Jun 10 20:43:54 EDT 2025
Wed Feb 19 02:23:56 EST 2025
Tue Jul 01 04:00:59 EDT 2025
Thu Apr 24 22:58:15 EDT 2025
Sat Sep 06 07:28:17 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Interstitial lung disease (ILD)
Primary Sjogren syndrome (pSS)
Th2 cells
Th1/Th2 ratio
Language English
License 2022. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c537t-d504db4cf18478656fecaab7f7825a57f59a3b97f7538542322fd8c165b3ea183
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://doi.org/10.1186/s13075-022-02811-z
PMID 35606782
PQID 2678148803
PQPubID 42876
PageCount 9
ParticipantIDs doaj_primary_oai_doaj_org_article_0b1e501d51fc49519c43b5d45523b7a0
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9125859
proquest_miscellaneous_2668907804
proquest_journals_2678148803
gale_infotracmisc_A706434887
gale_infotracacademiconefile_A706434887
pubmed_primary_35606782
crossref_citationtrail_10_1186_s13075_022_02811_z
crossref_primary_10_1186_s13075_022_02811_z
springer_journals_10_1186_s13075_022_02811_z
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-05-23
PublicationDateYYYYMMDD 2022-05-23
PublicationDate_xml – month: 05
  year: 2022
  text: 2022-05-23
  day: 23
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Arthritis research & therapy
PublicationTitleAbbrev Arthritis Res Ther
PublicationTitleAlternate Arthritis Res Ther
PublicationYear 2022
Publisher BioMed Central
BioMed Central Ltd
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: BMC
References M Polihronis (2811_CR39) 1998; 114
AJ Tyndall (2811_CR8) 2010; 69
MI Christodoulou (2811_CR12) 2010; 34
T Wang (2811_CR9) 2016; 34
A Suarez (2811_CR40) 2006; 65
B Efared (2811_CR1) 2017; 16
L Shi (2811_CR32) 2020; 20
SC Mathai (2811_CR5) 2016; 352
V Yazisiz (2811_CR24) 2010; 30
R Zhang (2811_CR22) 2014; 69
S Gupta (2811_CR7) 2019; 10
Q Wang (2811_CR17) 2018; 57
Y Wang (2811_CR21) 2018; 10
H Gao (2811_CR27) 2018; 21
Y Izumi (2811_CR33) 2006; 147
BK Davidson (2811_CR4) 2000; 59
P Pignatti (2811_CR31) 2006; 173
Z Amoura (2811_CR3) 2005; 14
O Palm (2811_CR23) 2013; 52
LA Aqrawi (2811_CR26) 2014; 177
L Zhang (2811_CR38) 2013; 33
J Wang (2811_CR18) 2020; 11
CH Shiboski (2811_CR15) 2017; 76
M Miao (2811_CR13) 2018; 77
J Gauldie (2811_CR37) 2007; 35
C Vitali (2811_CR14) 2002; 61
Y Enomoto (2811_CR20) 2013; 8
JA Trapani (2811_CR34) 2002; 2
G Raghu (2811_CR16) 2011; 183
SA Papiris (2811_CR29) 2005; 128
T Kimura (2811_CR28) 2006; 169
H Miyazaki (2811_CR35) 2004; 57
IG Luzina (2811_CR36) 2009; 60
DB Chandler (2811_CR10) 1983; 112
R Menor Almagro (2811_CR25) 2016; 12
FV Castelino (2811_CR2) 2010; 12
L Shi (2811_CR19) 2020; 11
F Meloni (2811_CR30) 2009; 27
X Dong (2811_CR6) 2018; 37
RS Thrall (2811_CR11) 1984; 129
NT Whitley (2811_CR41) 2011; 52
References_xml – volume: 52
  start-page: 70
  issue: 2
  year: 2011
  ident: 2811_CR41
  publication-title: J Small Anim Pract
  doi: 10.1111/j.1748-5827.2011.01024.x
– volume: 10
  start-page: 1327
  year: 2019
  ident: 2811_CR7
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2019.01327
– volume: 76
  start-page: 9
  issue: 1
  year: 2017
  ident: 2811_CR15
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2016-210571
– volume: 8
  start-page: e73774
  issue: 9
  year: 2013
  ident: 2811_CR20
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0073774
– volume: 183
  start-page: 788
  issue: 6
  year: 2011
  ident: 2811_CR16
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.2009-040GL
– volume: 169
  start-page: 96
  issue: 1
  year: 2006
  ident: 2811_CR28
  publication-title: Am J Pathol
  doi: 10.2353/ajpath.2006.051160
– volume: 33
  start-page: 1403
  issue: 6
  year: 2013
  ident: 2811_CR38
  publication-title: Rheumatol Int
  doi: 10.1007/s00296-012-2561-7
– volume: 61
  start-page: 554
  issue: 6
  year: 2002
  ident: 2811_CR14
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.61.6.554
– volume: 77
  start-page: 1838
  issue: 12
  year: 2018
  ident: 2811_CR13
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2018-213036
– volume: 12
  start-page: 256
  issue: 5
  year: 2016
  ident: 2811_CR25
  publication-title: Reumatol Clin
  doi: 10.1016/j.reuma.2015.10.010
– volume: 16
  start-page: 4
  issue: 1
  year: 2017
  ident: 2811_CR1
  publication-title: J Negat Results Biomed
  doi: 10.1186/s12952-017-0069-0
– volume: 69
  start-page: 1809
  issue: 10
  year: 2010
  ident: 2811_CR8
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2009.114264
– volume: 37
  start-page: 2981
  issue: 11
  year: 2018
  ident: 2811_CR6
  publication-title: Clin Rheumatol
  doi: 10.1007/s10067-018-4289-6
– volume: 34
  start-page: 587
  issue: 4
  year: 2016
  ident: 2811_CR9
  publication-title: Clin Exp Rheumatol
– volume: 11
  start-page: 1
  year: 2020
  ident: 2811_CR18
  publication-title: Ther Adv Chronic Dis
  doi: 10.1177/2040622320916014
– volume: 30
  start-page: 1317
  issue: 10
  year: 2010
  ident: 2811_CR24
  publication-title: Rheumatol Int
  doi: 10.1007/s00296-009-1152-8
– volume: 2
  start-page: 735
  issue: 10
  year: 2002
  ident: 2811_CR34
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri911
– volume: 52
  start-page: 173
  issue: 1
  year: 2013
  ident: 2811_CR23
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/kes311
– volume: 35
  start-page: 661
  issue: Pt 4
  year: 2007
  ident: 2811_CR37
  publication-title: Biochem Soc Trans
  doi: 10.1042/BST0350661
– volume: 112
  start-page: 170
  issue: 2
  year: 1983
  ident: 2811_CR10
  publication-title: Am J Pathol
– volume: 11
  start-page: 204062232094480
  year: 2020
  ident: 2811_CR19
  publication-title: Ther Adv Chronic Dis
  doi: 10.1177/2040622320944802
– volume: 59
  start-page: 709
  issue: 9
  year: 2000
  ident: 2811_CR4
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.59.9.709
– volume: 57
  start-page: 558
  issue: 8
  year: 2018
  ident: 2811_CR17
  publication-title: Chi J Intern Med
  doi: 10.3760/cma.j.issn.0578-1426.2018.08.005
– volume: 12
  start-page: 213
  issue: 4
  year: 2010
  ident: 2811_CR2
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar3097
– volume: 65
  start-page: 1512
  issue: 11
  year: 2006
  ident: 2811_CR40
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2005.049924
– volume: 60
  start-page: 1530
  issue: 5
  year: 2009
  ident: 2811_CR36
  publication-title: Arthritis Rheum
  doi: 10.1002/art.24435
– volume: 69
  start-page: 289
  issue: 2
  year: 2014
  ident: 2811_CR22
  publication-title: Cytokine
  doi: 10.1016/j.cyto.2014.06.008
– volume: 14
  start-page: 1279
  issue: 5
  year: 2005
  ident: 2811_CR3
  publication-title: Cancer Epidemiol Biomarkers Prev
  doi: 10.1158/1055-9965.EPI-04-0624
– volume: 21
  start-page: 1423
  issue: 7
  year: 2018
  ident: 2811_CR27
  publication-title: Int J Rheum Dis
  doi: 10.1111/1756-185X.13334
– volume: 34
  start-page: 400
  issue: 4
  year: 2010
  ident: 2811_CR12
  publication-title: J Autoimmun
  doi: 10.1016/j.jaut.2009.10.004
– volume: 10
  start-page: 2108
  issue: 4
  year: 2018
  ident: 2811_CR21
  publication-title: J Thorac Dis
  doi: 10.21037/jtd.2018.03.120
– volume: 147
  start-page: 242
  issue: 5
  year: 2006
  ident: 2811_CR33
  publication-title: J Lab Clin Med
  doi: 10.1016/j.lab.2006.01.001
– volume: 20
  start-page: 393
  issue: 3
  year: 2020
  ident: 2811_CR32
  publication-title: Clin Exp Med
  doi: 10.1007/s10238-020-00623-6
– volume: 114
  start-page: 485
  issue: 3
  year: 1998
  ident: 2811_CR39
  publication-title: Clin Exp Immunol
  doi: 10.1046/j.1365-2249.1998.00705.x
– volume: 129
  start-page: 279
  issue: 2
  year: 1984
  ident: 2811_CR11
  publication-title: Am Rev Respir Dis
– volume: 128
  start-page: 2971
  issue: 4
  year: 2005
  ident: 2811_CR29
  publication-title: Chest
  doi: 10.1378/chest.128.4.2971
– volume: 57
  start-page: 1292
  issue: 12
  year: 2004
  ident: 2811_CR35
  publication-title: J Clin Pathol
  doi: 10.1136/jcp.2003.015495
– volume: 352
  start-page: h6819
  year: 2016
  ident: 2811_CR5
  publication-title: BMJ
  doi: 10.1136/bmj.h6819
– volume: 173
  start-page: 310
  issue: 3
  year: 2006
  ident: 2811_CR31
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.200502-244OC
– volume: 27
  start-page: 765
  issue: 5
  year: 2009
  ident: 2811_CR30
  publication-title: Clin Exp Rheumatol
– volume: 177
  start-page: 244
  issue: 1
  year: 2014
  ident: 2811_CR26
  publication-title: Clin Exp Immunol
  doi: 10.1111/cei.12341
SSID ssj0022924
Score 2.4622579
Snippet Objective Primary Sjogren’s syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and...
Primary Sjogren's syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and the...
Objective Primary Sjogren's syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and...
Objective Primary Sjogren’s syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and...
Abstract Objective Primary Sjogren’s syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 121
SubjectTerms Age
Antibodies
Arthritis
Blood
Complications and side effects
Connective tissue
Development and progression
Exocrine glands
Flow cytometry
Health aspects
Immunology
Interstitial lung disease (ILD)
Laboratories
Lung diseases
Lung diseases, Interstitial
Lymphocytes
Measurement
Medical diagnosis
Medicine
Medicine & Public Health
Mortality
Orthopedics
Pathogenesis
Primary Sjogren syndrome (pSS)
Research Article
Respiratory system
Rheumatology
Risk factors
Sjogren's syndrome
T cells
Th1/Th2 ratio
Th2 cells
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQD4gL4p9AQUZC4gDRxrEdx8dSUVVI5UIr9Wb5L3RRm0W720tPPfcNeD2ehBnHWZoi4MJhDxuPI9szHs8X298Q8rrhvhONjKWuQwsAhcXSBs7LSkTBXYxWJp6Cg0_N_pH4eCyPr6X6wjNhAz3wMHCzyrEoKxYk6zwE80x7eIcMQgKCcsomtA5r3gimMtSqAVaMV2TaZrYCT63wJnINv5ax8mKyDCW2_t998rVF6eaByRu7pmkx2rtH7uYoku4Mrb9PbsX-Abl9kPfJH5Kr3fnSp8Rc_Rd6eFJT_D5Pl0jTioqgtg_wmM2waH7m8Hijj9QuI_WYrQMqxkDxEy39NrBR0M9fF4DM-x-X31d0ZDkobdYtCCPtxBLPHYA901PwIDRv_TwiR3sfDnf3y5x1ofSSq3UZZCWCE74D7KdaCPe66K11qoNYQlqpOqktdxr-g6-UuM9bd6H1rJGORwse4jHZ6hd9fEqoVZo5W3Ved1q4StlOBBGdZsE3gMtVQdioBOMzJTlmxjg1CZq0jRkUZ0BxJinOXBTk7aZOHoK_Sr9H3W4kkUw7PQATM9nEzL9MrCBv0DIMTnlonrf55gJ0EsmzzI7CuA48IXRoeyIJU9VPi0fbMtlVrEzdIOsYuFFekFebYqyJx9_6uDhHmabVFXJFFeTJYIqbLnGIWeEVdUHUxEgnfZ6W9POTRCSuIbptpS7Iu9GcfzXrz2P67H-M6XNyp07TUZY13yZb6-V5fAHh3dq9TDP5J8FsTC4
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbtQwELZgKyEuiH9SCjISEgeINk7sOD6htmpVIbVC0Eq9Wf5Lu6gkbXZ76Ykzb8Dr8STMZJ0tKaKHHBLbUZz5PJ7x2N8Q8rYsXM1LEVKV-wocFBZS44sizXjghQ3BiJ6nYP-g3Dvin47FcVxwm8dtlYNO7BW1bx2ukU_zEsmZAG3Fx_OLFLNGYXQ1ptC4S9ZABVdiQta2dg4-f1m5XLlaprXl4CvB1MqHYzNVOZ2D9pZ4OjmHq2IsvRpNTT2D_796-q-J6uYmyhuR1H6C2n1IHkTLkm4uofCI3AnNY3JvP8bOn5Cf27PO9cm6mhN6eJpTXLOnHVK3onCoaTw8ZlMsmn23uOXRBWq6QB1m8ICGwVNctqXnS4YK-vVbC9568_vHrzkdmA9SE-UNlZGKosO9CIBxegZahcZw0FNytLtzuL2XxkwMqROFXKReZNxb7mrwB2UFJmAdnDFW1mBfCCNkLZQprIJ70J8CY7957SvHSmGLYEBrPCOTpm3CC0KNVMyarHaqVtxm0tTc82AV864EX10mhA1C0C7SlGO2jDPduytVqZeC0yA43QtOXyXk_apN_AW31t5C2a5qIsF2_6DtTnQcrzqzLIiMecFqBz4kUw6gKzwX4LhbabKEvENkaFQD8HnOxNMM0Ekk1NKbEm09wCt0aGNUE4avGxcP2NJRfcz1NdgT8mZVjC1xS1wT2kusU1YqQ_6ohDxfQnHVpQLsWHhFnhA5Aumoz-OSZnbak4srsHgroRLyYYDz9Wf9_5-u396Ll-R-3g80kebFBpksusvwCoy5hX0dR-wf7ntHyw
  priority: 102
  providerName: ProQuest
Title Circulating Th2 cell reduction and Th1/Th2 imbalance are correlated with primary Sjogren’s syndrome-associated interstitial lung disease
URI https://link.springer.com/article/10.1186/s13075-022-02811-z
https://www.ncbi.nlm.nih.gov/pubmed/35606782
https://www.proquest.com/docview/2678148803
https://www.proquest.com/docview/2668907804
https://pubmed.ncbi.nlm.nih.gov/PMC9125859
https://doaj.org/article/0b1e501d51fc49519c43b5d45523b7a0
Volume 24
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZoKyEuiDeBsjISEgeIGidxHB-3q1YVUisEXWlvll-hW5Usym4vPXHmH_D3-CXMeJ2lKQ-JQyIlHkex5-EZj_2ZkFdVYZuy4j6VuashQGE-1a4o0qz0ZWG81zzgFByfVEfT8t2MzyJMDu6FuZ6_Z3W1twQbK3APcQ5XzVh6tUV2OOKMYWK2mmyCqxwCiX5TzB_rDQaegM__uxW-NgzdXCJ5I08ahp_De-Ru9BvpeM3o--SWbx-Q28cxM_6QfJvMOxuO4mo_0dOznOKMPO0QmBW7nurWwWu2h0XzzwYXNFpPdeepxfM5oKJ3FCdl6Zc1_gT9eL6AWLz98fX7kva4BqmO3ARiBJrocKUBSDC9AJtBY7LnEZkeHpxOjtJ4zkJqeSFWqeNZ6UxpG4j2RA0OXuOt1kY04D1wzUXDpS6MhGewjhwzu3njassqbgqvwSY8JtvtovVPCdVCMqOzxspGliYTuild6Y1kzlYQiYuEsJ4JykYQcjwL40KFYKSu1JpxChinAuPUVULebOrELvgn9T7ydkOJ8NnhBUiVitqoMsM8z5jjrLEQITJpQTC5KzmE5UboLCGvUTIUKjn8ntVxrwI0EuGy1FigJwe2Dxq0O6AE5bTD4l62VDQOS5VXiDMGhrNIyMtNMdbEBW-tX1wiTVXLDNGhEvJkLYqbJhXgpcIn8oSIgZAO2jwsaednATpcgj9bc5mQt704__qtv_fps_8jf07u5EHxeJoXu2R71V36F-C6rcyIbImZGJGd_YOT9x9GQYNHYRoE7tN8_BOTTkIy
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3LbtQwFLVKKwEbxJtAASOBWEA0sRMn8QKhtrSa0s4IwVTqzji2Mx1UMiUzFaIr1vwBP8FH8SXcm8eUFNFdF1kkfijOfefa5xLyNA5NHsXC-ZLbFAIU5nxtw9APIheFmXNaVDgFg2Hc34ve7ov9JfKrPQuD2ypbnVgpajs1-I-8x2MEZwJuC18fffGxahRmV9sSGjVb7LhvXyFkm73afgP0fcb51uZoo-83VQV8I8Jk7lsRRDaLTA6xTZKCO5M7o3WW5GArhRZJLqQOMwn3oAsE5jF5blPDYpGFToMEwLyXyAq4GRKkaGV9c_ju_SLE47Iuowsz-2DKo_aYThr3ZmAtEjwNzeFKGfNPOqawqhjwr134yzCe3bR5JnNbGcSt6-Ra48nStZr1bpAlV9wklwdNrv4W-bExKU1VHKwY09EBp5gjoCVCxSIzUF1YeMx62DT5nOEWS-OoLh01WDEEBjpL8TcxPaoRMeiHT9Nx6Yrf33_OaIu04OuGv6AzQl-UuPcBZIoeghajTfrpNtm7EBrdIcvFtHD3CNWJZJkOciNzGWVBovPIRi6TzJo4ACvhEdYSQZkGFh2rcxyqKjxKY1UTTgHhVEU4deKRF4sxzSc4t_c60nbREwG9qwfTcqwa_aCCjDkRMCtYbiBmZdKAqAgbCcHDLNGBR54jZyhUO_B6RjenJ2CRCOCl1hL0LUE-YEGrnZ6gLky3ueUt1airmToVLo88WTTjSNyCV7jpMfaJUxkgXpVH7tasuFhSCH4zTME9knSYtLPmbksxOajAzCV42KmQHnnZsvPpa_3_m94_fxWPyZX-aLCrdreHOw_IVV4JnfB5uEqW5-WxewiO5Dx71EgvJR8vWmH8AfWDhFY
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZgK1VcEG8CBYyExAGijZM4jo9LYVUWWiG1lXqz_GwXlWyV3V564sw_4O_xS5jJY2nKQ-Kwh8TjVZx5eCYz85mQF0VmQ15wH8vUlRCgMB9rl2Vxkvs8M95r3uAU7O4VO4f57IgfXerib6rd-5Rk29OAKE3VanzmQqviZTFeguUV2Fmcwq9kLL64TjbKAtyHEdmYTGb7s3XQlUKA0TfL_HHmYENqcPt_t86XtqerpZNX8qfNtjS9RW52_iSdtAJwm1zz1R2yudtlzO-Sb9vz2jZHdFXH9OAkpfilntYI2IosobpycJuNcWj-xWCho_VU155aPLcDJnpH8WMtPWtxKej-5wXE6NWPr9-XtMc7iHXHZSBGAIoaKxBAsukp2BLaJYHukcPpu4Ptnbg7fyG2PBOr2PEkdya3AaJAUYLjF7zV2ogAXgXXXAQudWYkXIPV5JjxTYMrLSu4ybwGW3GfjKpF5R8SqoVkRifByiBzkwgdcpd7I5mzBUToIiKsZ4KyHTg5npFxqpogpSxUyzgFjFMN49RFRF6t53Sv4J_Ub5C3a0qE1W5uLOpj1WmpSgzzPGGOs2AhcmTSgsByl3MI143QSUReomQoVH54PKu7HgZYJMJoqYlADw9sIixoa0AJSmuHw71sqc5oLFVaIP4YGNQsIs_XwzgTC-EqvzhHmqKUCaJGReRBK4rrJWXgvcJfpBERAyEdrHk4Us1PGkhxCX5uyWVEXvfi_Oux_v5OH_0f-TOy-entVH18v_fhMbmRNjrI4zTbIqNVfe6fgHe3Mk87Bf4JITRKbg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Circulating+Th2+cell+reduction+and+Th1%2FTh2+imbalance+are+correlated+with+primary+Sjogren%27s+syndrome-associated+interstitial+lung+disease&rft.jtitle=Arthritis+research+%26+therapy&rft.au=Shi%2C+Lei&rft.au=Wang%2C+Jia&rft.au=Guo%2C+Hong-Xia&rft.au=Han%2C+Xiao-Lei&rft.date=2022-05-23&rft.eissn=1478-6362&rft.volume=24&rft.issue=1&rft.spage=121&rft_id=info:doi/10.1186%2Fs13075-022-02811-z&rft_id=info%3Apmid%2F35606782&rft.externalDocID=35606782
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-6362&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-6362&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-6362&client=summon